BIO 2020: Day 1 Kicked Off With New CEO, Focus on COVID-19 Published: June 9, 2020 By Alex Keown BioSpace   The annual Biotechnology Innovation Organization (BIO) meeting kicked off Monday with the proverbial passing of the baton from longtime head Jim Greenwood to Michelle McMurry-Heath, who was tapped to take over the organization last month. […]

Join the Marken team and industry experts to learn about new supply chain industry trends and how companies can prepare to move clinical trials forward post-pandemic.

The age of blockbuster drugs has officially given way to precision medicines that are customized for rare diseases and individual patients. We are in the early days of a decades-long trend that will influence changes throughout the entire life sciences industry and lead to groundbreaking cures and treatments.

CMI/Compas created a Growth & Innovation practice that is expected to keep clients ahead of the curve by prioritizing and investing in innovation.

CMI/Compas – media strategy, planning, innovation and buying for the nation’s top healthcare companies and part of WPP – has created a Growth & Innovation practice to keep clients ahead of the curve by prioritizing and investing in innovation.

What will top the agenda of new U.S. FDA Commissioner Dr. Stephen Hahn?

In light of the Thanksgiving season, here are six things about biopharma that the industry is thankful for.

AstraZeneca is significantly expanding the company’s footprint in China with the establishment of a global R&D center and launch of a $1 billion fund aimed at supporting that nation’s healthcare sector.

Innovations in diabetes care go beyond new therapeutic classes. Pharmaceutical companies are continuing to invest in new technology to help improve diabetes treatment and patient adherence with progress ranging from artificial pancreases to smart insulin pens and pumps.